Stifel raised the firm’s price target on Abbott (ABT) to $135 from $130 and keeps a Buy rating on the shares. The firm views Abbott’s Q4 results and the 2025 set-up “positively,” arguing that momentum in the company’s Diabetes Care business and Structural Heart business “appears primed to drive another year of double-digit Medical Device division growth” and high-single-digit total company growth, the analyst tells investors in a post-earnings note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target raised to $138 from $135 at Bernstein
- Abbott price target raised to $148 from $146 at UBS, shares remain undervalued
- Abbott Laboratories Reports Strong 2024 Financial Results
- Abbott price target raised to $140 from $139 at BTIG
- Netflix, Seagate, J&J report quarterly beats: Morning Buzz